# CS MEDICA a/s

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/csmedica).

## Overview

CS MEDICA a/s is a Danish MedTech company founded in 2011 that develops and sells CBD-infused medical device products and cosmetics. Its business combines product development, regulatory progression, and commercialization under one corporate structure, with operations centered in Denmark.

## Products & services

• CBD-infused medical device products
• CBD-based cosmetics
• Product development and formulation
• Regulatory approval and market launch support

- **CBD medical devices** (60%) — Medical device products formulated with CBD for wellness or therapeutic use cases.
- **CBD cosmetics** (30%) — Topical cosmetic products containing CBD and related ingredients.
- **Development services** (10%) — Internal development, testing, and regulatory work supporting new product launches.

- CBD-infused medical device products
- CBD-based cosmetics
- Product development and formulation
- Regulatory approval and market launch support

## Customers

CS MEDICA sells to buyers interested in CBD-based consumer health and personal care products, including retail channels and other distribution partners. Its end customers are typically consumers and users seeking topical or device-based CBD products, while the commercial buyer may be a distributor, reseller, or channel partner. Regulatory compliance and product positioning matter because the products sit at the intersection of medtech, cosmetics, and wellness.

- **Consumer wellness buyers** (primary) — Buy CBD-based products for personal care, comfort, or wellness use.
- **Retail and distribution partners** (primary) — Buy products for resale through shops, web channels, or local distribution.
- **Regulated channel buyers** (secondary) — Buy compliant products that can be marketed within medical-device or cosmetic rules.

- Consumers buying CBD wellness and topical care products
- Retail and distribution partners for consumer health products
- Channel buyers seeking compliant CBD product assortments
- End users looking for CBD-based device or cosmetic formats

## Geography

The company is based in Denmark and its operating footprint is anchored there. The available report excerpt does not disclose a broader country revenue split, so the business should be viewed as Denmark-centered with potential exposure to export and cross-border distribution as products are commercialized. Geography matters because regulatory approval, labeling, and market access for CBD products can vary significantly by country.

- Headquartered and founded in Denmark
- Current disclosure does not provide a country revenue split
- Likely exposed to cross-border CBD regulation and labeling rules
- Market access depends on local rules for medical devices and cosmetics

## Strategy

CS MEDICA's strategy is centered on developing CBD-infused products through the clinical, regulatory, and launch stages described in its development pathway. The company’s competitive position depends on moving products from concept and feasibility into marketable offerings that can be sold through compliant channels. Building a portfolio across medical-device and cosmetic formats also broadens its addressable market and reduces reliance on a single product type.

- **Regulatory progression** (short-term) — CBD products in medtech and cosmetics need compliance before broad commercialization.
- **Product commercialization** (short-term) — Revenue depends on turning developed products into market launches and sales.
- **Portfolio expansion** (medium-term) — A broader portfolio can spread regulatory and demand risk across more products.

- Advance products through development and regulatory approval stages
- Commercialize CBD products in medical-device and cosmetic formats
- Expand the product portfolio beyond a single application
- Use compliance and formulation expertise as a market barrier
- Convert R&D work into sellable products and recurring demand

## Risks

The main risks come from regulation, product acceptance, and the complexity of commercializing CBD-related healthcare and cosmetic products. Because the business depends on approvals, labeling, and market access, changes in rules or delays in development can materially slow commercialization. There is also execution risk in converting R&D activity into products that achieve sustained demand through distributors or other channels.

- **Regulatory restrictions on CBD products** [high] — Sales depend on legal classification, approvals, and country-specific compliance.
- **Product development failure** [high] — Products must progress through feasibility, R&D, and approval before scaling.
- **Customer and channel concentration** [medium] — A small number of distributors or buyers can create revenue volatility.

- CBD regulatory changes can delay or block product sales
- Commercialization risk if new products fail to gain market acceptance
- R&D and launch execution risk across multiple development stages
- Dependence on compliant labeling and product classification
- Channel concentration risk if sales rely on few distributors

## Accounting

The most important accounting judgments are likely tied to development costs, product launch timing, and valuation of intangible assets related to the CBD pipeline. Because the company is at the intersection of development and commercialization, investors should watch how capitalized development expenses, provisions, and any impairment assessments affect reported results. Revenue recognition may also depend on when products are delivered to customers and whether any returns, rebates, or launch-related adjustments are present.

- **Development cost accounting** — Affects EBIT and the carrying value of intangible assets
- **Impairment of intangibles** — Can create non-cash charges and reduce equity
- **Revenue recognition** — Affects quarterly comparability and reported growth
- **Warrants and equity instruments** — May affect diluted share count and equity valuation

- Capitalization versus expensing of development costs
- Impairment testing for product-related intangibles
- Revenue timing around product shipment and delivery
- Provisions for regulatory, launch, or warranty-related items
- Fair value of warrants and equity-linked instruments

---

*Last updated: 2026-10-24T15:04:35.223055+00:00*